Compare VTS & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | DNA |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 756.5M | 607.1M |
| IPO Year | 2022 | N/A |
| Metric | VTS | DNA |
|---|---|---|
| Price | $19.37 | $6.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.50 | $10.50 |
| AVG Volume (30 Days) | 441.7K | ★ 1.0M |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $29.38 | $1.60 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.41 | ★ N/A |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $17.44 | $5.00 |
| 52 Week High | $27.15 | $17.58 |
| Indicator | VTS | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 35.01 |
| Support Level | $19.21 | $6.54 |
| Resistance Level | $20.24 | $10.05 |
| Average True Range (ATR) | 0.84 | 0.63 |
| MACD | -0.36 | -0.27 |
| Stochastic Oscillator | 36.93 | 5.85 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.